Molecular epidemiology and disease severity of influenza virus infection in patients with haematological disorders
- PMID: 37249242
- DOI: 10.1002/jmv.28835
Molecular epidemiology and disease severity of influenza virus infection in patients with haematological disorders
Abstract
Influenza virus infection is a common cause of self-limiting respiratory tract infection (RTI), however immunocompromised patients are at an increased risk for a severe course of disease or fatal outcome. We therefore aimed to gain a better understanding of the molecular epidemiology of influenza viruses from patients with haematological disorders and their impact on the clinical course of disease. Molecular analysis using polymerase chain reaction (PCR) of nasopharyngeal swabs was performed for influenza virus in haematological patients at the Heidelberg University Hospital. Clinical data was evaluated to identify associated risk factors. For phylogenetic analysis, the hemagglutinin (HA) gene was sequenced. Out of 159 influenza positive patients, 117 patients developed upper RTI (influenza A: n = 73; influenza B: n = 44). Lower RTI was observed in n = 42 patients (26%), n = 22/42 patients developed severe disease and n = 16/159 (10.1%) patients died. Risk factors for lower RTI were nosocomial infection (p = 0.02), viral shedding for ≥14 days (p = 0.018), IgG levels <6 g/dL (p = 0.046), bacterial/fungal co-infections (p < 0.001). Risk factors for fatal outcome were age ≥65 years (p = 0.032), bacterial/fungal (p≤0.001) co-infections and high viral load (p = 0.026). Sequencing of the HA gene (n = 115) revealed subtype A(H3N2) (n = 46), A(H1N1)pdm09 (n = 24), B/Victoria (n = 34), B/Yamagata (n = 11). There was no correlation between influenza (sub)type and lower RTI. Influenza infection in haematological patients is associated with significant morbidity and mortality, the risk for aggravating co-infections, prolonged viral shedding and nosocomial transmission emphasizing the need for infection control.
Keywords: haematologic disorder; influenza virus; molecular epidemiology; risk factors.
© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
References
REFERENCES
-
- Von lilienfeld-Toal M, Berger A, Christopeit M, et al. Community acquired respiratory virus infections in cancer patients-guideline on diagnosis and management by the infectious diseases working party of the German society for haematology and medical oncology. Eur J Cancer. 2016;67:200-212. doi:10.1016/j.ejca.2016.08.015
-
- Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39(9):1300-1306. doi:10.1086/425004
-
- Hermann B, Lehners N, Brodhun M, et al. Influenza virus infections in patients with malignancies--characteristics and outcome of the season 2014/15. A survey conducted by the infectious diseases working party (AGIHO) of the German society of haematology and medical oncology (DGHO). Eur J Clin Microbiol Infect Dis. 2017;36(3):565-573. doi:10.1007/s10096-016-2833-3
-
- Lehners N, Tabatabai J, Prifert C, et al. Long-term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders. PLoS One. 2016;11(2):e0148258. doi:10.1371/journal.pone.0148258
-
- Yue MC, Collins JT, Subramoniapillai E, Kennedy GA. Successful use of oseltamivir prophylaxis in managing a nosocomial outbreak of influenza A in a hematology and allogeneic stem cell transplant unit. Asia Pac J Clin Oncol. 2017;13(1):37-43. doi:10.1111/ajco.12565
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
